Expression of CD103 identifies human regulatory T-cell subsets - 20/08/11
Montreal, Quebec, Canada, and Seattle, Wash
Abstract |
Background |
Analysis of naturally occurring T regulatory CD4+ (nTreg) cells in human diseases is hampered by the lack of specific surface marker. Indeed, the CD25 antigen, which is typically used to identify nTreg cells, is also expressed on activated effector T cells.
Objective |
We sought to examine whether CD4+ T cells bearing CD103 are suppressor cells, regardless of CD25 coexpression.
Methods |
We first compared freshly isolated tonsillar CD103+CD25− cells with their CD103−CD25high counterparts for their capacity to suppress T-cell response and their expression of FoxP3 mRNA. Next CD103 was induced on neonatal or adult CD4+ T cells stimulated with allogeneic dendritic cells, and the CD103+ and CD103− fractions were compared as above.
Results |
Tonsillar CD4+CD103+CD25− T cells displayed comparable suppressive activity and contained similar amounts of FoxP3 mRNA as their CD103−CD25high counterparts. In vitro–generated alloantigen-primed CD103+ cells coexpressed CD25, suppressed T-cell activation, and contained more FoxP3 mRNA than the CD103−CD25+ cells isolated from the same cultures. Finally, neonatal alloreactive cells contained more CD103+ Treg cells than their adult counterparts and, unlike the latter, became hyporesponsive to the priming alloantigens.
Conclusions |
The examination of CD103 and CD25 coexpression allows identification of 3 subsets of human CD4+ nTreg cells, and the detection of CD103 on CD4+ T cells identifies nTreg cells, regardless of CD25 coexpression.
Clinical implications |
The greater induction of CD103+ suppressor cells by cord blood should be related to its successful clinical use as an alternative to adult bone marrow transplantation.
El texto completo de este artículo está disponible en PDF.Key words : Human regulatory T cells, CD103, FoxP3, CD25, neonatal lymphocytes, dendritic cells, alloreactive T cells, TGF-β
Abbreviations used : DC, FITC, iDC, mDC, PE, TCR, Treg
Esquema
Supported in part by a Canadian Institute of Health Research grant MOP 103957. Disclosure of potential conflict of interest: D. Fitzpatrick is employed by and owns stock in Amgen. The rest of the authors have declared that they have no conflict of interest. |
Vol 118 - N° 6
P. 1342-1349 - décembre 2006 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?